BRD2 and ovarian carcinoma: They loaded HK II shRNA onto a PEG-PEI copolymer that was conjugated with FSH peptide along with reverse-transcribed FSH peptide, and this approach selectively inhibited the expression of HK II in ovarian cancer [175].